Relationship Between Janus Kinase Inhibitor Use and Development of Retinal Vein Occlusion.

IF 0.9 4区医学 Q4 OPHTHALMOLOGY Ophthalmic surgery, lasers & imaging retina Pub Date : 2025-02-01 Epub Date: 2024-09-01 DOI:10.3928/23258160-20240908-01

Meghana Chalasani, Jonathan C Markle, Priya Shukla, Rula A Hajj-Ali, Katherine E Talcott, Rishi P Singh

{"title":"Relationship Between Janus Kinase Inhibitor Use and Development of Retinal Vein Occlusion.","authors":"Meghana Chalasani, Jonathan C Markle, Priya Shukla, Rula A Hajj-Ali, Katherine E Talcott, Rishi P Singh","doi":"10.3928/23258160-20240908-01","DOIUrl":null,"url":null,"abstract":"Background and objective: Janus kinase (Jak) inhibitors may have increased risk of thromboembolism compared to tumor necrosis factor (TNF) inhibitors. This study investigates the association between Jak inhibitor use and retinal vein occlusion.Patients and methods: This retrospective, non-randomized cohort study used a federated health research network. Propensity-score matched risk ratios with 95% CI were calculated for central and branch retinal vein occlusion (CRVO, BRVO) in patients with immune-mediated inflammatory diseases (IMIDs) treated with Jak inhibitors versus TNF inhibitors.Results: Jak and TNF inhibitor cohorts each had 5,249 patients. Risk ratio for CRVO with Jak inhibitors (n = 11) versus TNF inhibitors (n = 18) was 0.61 [CI (0.29,1.29)]. Risk ratio for BRVO with Jak inhibitors (n = 17) compared to TNF inhibitors (n = 19) was 0.89 [CI (0.47,1.72)].Conclusion: This study did not find evidence of increased risk of RVO with the use of Jak inhibitors compared to TNF inhibitors among patients with IMIDs, contributing to literature on Jak inhibitor safety. [Ophthalmic Surg Lasers Imaging Retina 2025;56:72-78.].","PeriodicalId":19679,"journal":{"name":"Ophthalmic surgery, lasers & imaging retina","volume":" ","pages":"72-78"},"PeriodicalIF":0.9000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ophthalmic surgery, lasers & imaging retina","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3928/23258160-20240908-01","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/1 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background and objective: Janus kinase (Jak) inhibitors may have increased risk of thromboembolism compared to tumor necrosis factor (TNF) inhibitors. This study investigates the association between Jak inhibitor use and retinal vein occlusion.

Patients and methods: This retrospective, non-randomized cohort study used a federated health research network. Propensity-score matched risk ratios with 95% CI were calculated for central and branch retinal vein occlusion (CRVO, BRVO) in patients with immune-mediated inflammatory diseases (IMIDs) treated with Jak inhibitors versus TNF inhibitors.

Results: Jak and TNF inhibitor cohorts each had 5,249 patients. Risk ratio for CRVO with Jak inhibitors (n = 11) versus TNF inhibitors (n = 18) was 0.61 [CI (0.29,1.29)]. Risk ratio for BRVO with Jak inhibitors (n = 17) compared to TNF inhibitors (n = 19) was 0.89 [CI (0.47,1.72)].

Conclusion: This study did not find evidence of increased risk of RVO with the use of Jak inhibitors compared to TNF inhibitors among patients with IMIDs, contributing to literature on Jak inhibitor safety. [Ophthalmic Surg Lasers Imaging Retina 2025;56:72-78.].

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Janus 激酶抑制剂的使用与视网膜静脉闭塞发展之间的关系

背景和目的：与肿瘤坏死因子（TNF）抑制剂相比，Janus 激酶（Jak）抑制剂可能会增加血栓栓塞的风险。本研究调查了Jak抑制剂的使用与视网膜静脉闭塞之间的关联：这项回顾性非随机队列研究使用了一个联合健康研究网络。计算了接受Jak抑制剂与TNF抑制剂治疗的免疫介导炎症性疾病（IMIDs）患者视网膜中央静脉闭塞和视网膜分支静脉闭塞（CRVO、BRVO）的倾向分数匹配风险比及95% CI：Jak抑制剂组和TNF抑制剂组各有5249名患者。使用Jak抑制剂（n = 11）与TNF抑制剂（n = 18）治疗CRVO的风险比为0.61 [CI (0.29,1.29)]。使用Jak抑制剂（n = 17）与TNF抑制剂（n = 19）相比，BRVO的风险比为0.89 [CI (0.47,1.72)]：本研究未发现IMIDs患者使用Jak抑制剂比TNF抑制剂增加RVO风险的证据，为Jak抑制剂安全性方面的文献做出了贡献。[眼科手术激光成像视网膜2024;55:xx-xx]。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Ophthalmic surgery, lasers & imaging retina OPHTHALMOLOGY-SURGERY

CiteScore

1.80

自引率

0.00%

发文量

期刊介绍： OSLI Retina focuses exclusively on retinal diseases, surgery and pharmacotherapy. OSLI Retina will offer an expedited submission to publication effort of peer-reviewed clinical science and case report articles. The front of the journal offers practical clinical and practice management features and columns specific to retina specialists. In sum, readers will find important peer-reviewed retina articles and the latest findings in techniques and science, as well as informative business and practice management features in one journal.